SCRIB and breast carcinoma: High levels of SCRIB mRNA expression correlated with poor clinical survival in the patients with ER+/progesterone receptor-positive (PR+) status (Fig. 1a) whereas SCRIB mRNA expression did not correlate with poor clinical survival in the patients with ER−/PR+, ER+/PR−, ER−/PR−, HER2+, and ER−/PR−/HER2− status (Supplementary Fig. 1 b–f), leading us to investigate the pathological roles of SCRIB in ER+ breast cancer cells.